S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden's Plan to Confiscate Your Cash? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden's Plan to Confiscate Your Cash? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden's Plan to Confiscate Your Cash? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden's Plan to Confiscate Your Cash? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:PBLA

Panbela Therapeutics - PBLA Stock Forecast, Price & News

$1.29
-0.08 (-5.84%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.29
$1.37
50-Day Range
$0.61
$1.44
52-Week Range
$0.59
$2.54
Volume
10,843 shs
Average Volume
15,037 shs
Market Capitalization
$26.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Panbela Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
598.0% Upside
$9.00 Price Target
Short Interest
Healthy
0.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Panbela Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.84) to ($0.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

635th out of 1,135 stocks

Pharmaceutical Preparations Industry

322nd out of 557 stocks

PBLA stock logo

About Panbela Therapeutics (NASDAQ:PBLA) Stock

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Analysts Set New Price Targets

Separately, Maxim Group assumed coverage on Panbela Therapeutics in a research note on Friday, May 13th. They issued a "buy" rating and a $5.00 price target for the company.

Panbela Therapeutics Stock Down 5.9 %

NASDAQ:PBLA traded down $0.08 during trading on Friday, hitting $1.29. 10,843 shares of the company's stock were exchanged, compared to its average volume of 15,037. Panbela Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $2.54. The stock's 50 day moving average price is $1.16 and its two-hundred day moving average price is $1.61.

Panbela Therapeutics (NASDAQ:PBLA - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.01). During the same period in the previous year, the business earned ($0.23) earnings per share. As a group, analysts forecast that Panbela Therapeutics will post -0.84 earnings per share for the current fiscal year.

Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PBLA Stock News Headlines

Panbela Therapeutics (PBLA) Set to Announce Earnings on Monday
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Short Interest Update
Panbela Therapeutics GAAP EPS of -$0.27
Panbela to Host Virtual R&D Day
Panbela Therapeutics GAAP EPS of -$0.26
Preview: Panbela Therapeutics's Earnings
Panbela Therapeutics, Inc. (PBLA)
See More Headlines
Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PBLA Company Calendar

Last Earnings
11/10/2021
Today
8/14/2022
Next Earnings (Confirmed)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PBLA
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+598.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.76 per share

Miscellaneous

Free Float
17,076,000
Market Cap
$26.78 million
Optionable
Not Optionable
Beta
2.35

Key Executives

  • Dr. Jennifer K. Simpson C.R.N.P. (Age 54)
    CRNP, M.S.N., Ph.D., CEO, Pres & Director
    Comp: $659.03k
  • Ms. Susan Horvath (Age 63)
    VP of Fin., CFO, Sec. & Treasurer
    Comp: $401.82k
  • Ms. Tammy Groene
    VP of Operations
  • Dr. Elizabeth Bruckheimer Ph.D.
    VP & Chief Scientific Officer













PBLA Stock - Frequently Asked Questions

Should I buy or sell Panbela Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Panbela Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBLA shares.
View PBLA analyst ratings
or view top-rated stocks.

What is Panbela Therapeutics' stock price forecast for 2022?

1 brokers have issued 1 year target prices for Panbela Therapeutics' stock. Their PBLA share price forecasts range from $5.00 to $13.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 598.0% from the stock's current price.
View analysts price targets for PBLA
or view top-rated stocks among Wall Street analysts.

How have PBLA shares performed in 2022?

Panbela Therapeutics' stock was trading at $1.7301 on January 1st, 2022. Since then, PBLA shares have decreased by 25.5% and is now trading at $1.2894.
View the best growth stocks for 2022 here
.

When is Panbela Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our PBLA earnings forecast
.

How can I listen to Panbela Therapeutics' earnings call?

Panbela Therapeutics will be holding an earnings conference call on Monday, August 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "45649".

How were Panbela Therapeutics' earnings last quarter?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. During the same quarter in the prior year, the business earned ($0.21) EPS.

What is Panbela Therapeutics' stock symbol?

Panbela Therapeutics trades on the NASDAQ under the ticker symbol "PBLA."

How do I buy shares of Panbela Therapeutics?

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Panbela Therapeutics' stock price today?

One share of PBLA stock can currently be purchased for approximately $1.29.

How much money does Panbela Therapeutics make?

Panbela Therapeutics (NASDAQ:PBLA) has a market capitalization of $26.78 million. The company earns $-10,140,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How can I contact Panbela Therapeutics?

Panbela Therapeutics' mailing address is 712 VISTA BLVD SUITE 305, WACONIA MN, 55387. The official website for the company is www.panbela.com. The company can be reached via phone at (952) 479-1196 or via email at investors@neoleukin.com.

This page (NASDAQ:PBLA) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.